- Business Wire•6 hours agoKEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology
Merck , known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA® , the company’s anti-PD-1 therapy, in two trials of patients with relapsed or refractory classical Hodgkin lymphoma .
- Investor's Business Daily•9 hours ago
The major averages ended on the positive side Monday, with the Nasdaq taking the lead as several chip stocks rallied.
- Forbes•12 hours ago
Medical breakthroughs of every type were were discussed at Forbes’ 2016 Healthcare Summit last week. But the issue that reemerged most relentlessly throughout the day? Pricing.
MRK : Summary for Merck & Company, Inc. Common St - Yahoo Finance
Merck & Co., Inc. (MRK)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||60.24 x 100|
|Ask||60.30 x 400|
|Day's Range||59.84 - 61.52|
|52 Week Range||47.97 - 65.46|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||30.77|
|Dividend & Yield||1.88 (3.08%)|
|1y Target Est||N/A|